Author

Balaji Balasa

Observed names: B Balasa, B. Balasa

Observed institutions: Scripps Research Institute, Trudeau Institute, Memorial University of Newfoundland, Harvard University, Dana-Farber Cancer Institute, Hôpital Purpan, PDL BioPharma (United States), AbbVie Biotherapeutics (United States), The University of Texas Medical Branch at Galveston, University of Arkansas for Medical Sciences

OpenAlex ID: A5078553844

CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma

2008 · Eric D. Hsi, Roxanne Steinle, et al. · Clinical Cancer Research · 559

PDF

CD40 ligand-CD40 interactions are necessary for the initiation of insulitis and diabetes in nonobese diabetic mice

1997 · B Balasa, T Krahl, et al. · The Journal of Immunology · 241

Interferon γ (IFN-γ) Is Necessary for the Genesis of Acetylcholine Receptor–induced Clinical Experimental Autoimmune Myasthenia gravis in Mice

1997 · Balaji Balasa, Caishu Deng, et al. · The Journal of Experimental Medicine · 183

PDF

Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma

2009 · Frits van Rhee, Susann M. Szmania, et al. · Molecular Cancer Therapeutics · 176

PDF

Germ line deletion of the CD1 locus exacerbates diabetes in the NOD mouse

2001 · Fu-Dong Shi, Malin Flodström, et al. · Proceedings of the National Academy of Sciences · 173

Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-α pathways

2014 · Balaji Balasa, Rui Yun, et al. · Cancer Immunology Immunotherapy · 157

PDF

Pancreatic IL-4 Expression Results in Islet-Reactive Th2 Cells That Inhibit Diabetogenic Lymphocytes in the Nonobese Diabetic Mouse

1999 · W Scott Gallichan, Balaji Balasa, et al. · The Journal of Immunology · 84

The Th2 Cytokine IL-4 Is Not Required for the Progression of Antibody-Dependent Autoimmune Myasthenia Gravis

1998 · Balaji Balasa, Caishu Deng, et al. · The Journal of Immunology · 70

PDF

A Mechanism for IL-10-Mediated Diabetes in the Nonobese Diabetic (NOD) Mouse: ICAM-1 Deficiency Blocks Accelerated Diabetes

2000 · Balaji Balasa, Antonio La Cava, et al. · The Journal of Immunology · 67

PDF

Vaccination with Glutamic Acid Decarboxylase Plasmid DNA Protects Mice from Spontaneous Autoimmune Diabetes and B7/CD28 Costimulation Circumvents That Protection

2001 · Balaji Balasa, Bernhard O. Boehm, et al. · Clinical Immunology · 56

The Paradoxical Effects of Interleukin 10 in the Immunoregulation of Autoimmune Diabetes

1996 · Balaji Balasa, Nora Sarvetnick · Journal of Autoimmunity · 56

IL-10 Impacts Autoimmune Diabetes Via a CD8+ T Cell Pathway Circumventing the Requirement for CD4+ T and B Lymphocytes

1998 · Balaji Balasa, Joanna D Davies, et al. · The Journal of Immunology · 55

PDF

Islet-Specific Expression of IL-10 Promotes Diabetes in Nonobese Diabetic Mice Independent of Fas, Perforin, TNF Receptor-1, and TNF Receptor-2 Molecules

2000 · Balaji Balasa, Kurt Van Gunst, et al. · The Journal of Immunology · 49

Is pathogenic humoral autoimmunity a Th1 response? Lessons from (for) myasthenia gravis

2000 · Balaji Balasa, Nora Sarvetnick · Immunology Today · 45

CCR2 and CCR5 chemokine receptors differentially influence the development of autoimmune diabetes in the NOD mouse

2009 · Michelle Solomon, Balaji Balasa, et al. · Autoimmunity · 35

IL-10 Deficiency Does Not Inhibit Insulitis and Accelerates Cyclophosphamide-Induced Diabetes in the Nonobese Diabetic Mouse

2000 · Balaji Balasa, Kurt Van Gunst, et al. · Cellular Immunology · 32

Mapping of thyroglobulin epitopes: Presentation of a 9mer pathogenic peptide by different mouse MHC class II isotypes

1994 · Varanda P. Rao, Balaji Balasa, et al. · Immunogenetics · 32

The Microbial Product Lipopolysaccharide Confers Diabetogenic Potential on the T Cell Repertoire of BDC2.5/NOD Mice: Implications for the Etiology of Autoimmune Diabetes

2000 · Balaji Balasa, Kurt Van Gunst, et al. · Clinical Immunology · 23

Induction of Experimental Autoimmune Thyroiditis in Rats with the Synthetic Peptide (2495-2511) of Thyroglobulin

1993 · Balaji Balasa, George Carayanniotis · Cellular Immunology · 17

Effect of Elotuzumab on Circulating Lymphocytes, Chemokines, and Cytokines In Multiple Myeloma Patients

2010 · Lauri Neyer, Han Ding, et al. · Blood · 11

CS1: A Potential New Therapeutic Target for the Treatment of Multiple Myeloma.

2006 · Eric D. Hsi, Roxanne Steinle, et al. · Blood · 7

Differential Impact of T Cell Repertoire Diversity in Diabetes-Prone or -Resistant IL-10 Transgenic Mice

1999 · Balaji Balasa, Jae Lee, et al. · Cellular Immunology · 7

Natural killer (NK) cell activation, cytokine production, and cytotoxicity in human PBMC/myeloma cell co-culture exposed to elotuzumab (Elo) alone or in combination with lenalidomide (Len).

2012 · Balaji Balasa, Rui Yun, et al. · Journal of Clinical Oncology · 6

CS1 Is Expressed on Myeloma Cells from Early Stage, Late Stage, and Drug-Treated Multiple Myeloma Patients, and Is Selectively Targeted by the HuLuc63 Antibody.

2006 · Susann Szmania, Balaji Balasa, et al. · Blood · 6

Elotuzumab (HuLuc63) Activates CD56dim Natural Killer Cells and Monocytes Resulting in the Release of IP-10 and MCP-1

2008 · Balaji Balasa, Mahrukh Huseni, et al. · Blood · 5

Works count: 40

Citation count: 2,171

H-index: 18

I10-index: 20